FDA-APPROVED INDICATIONS Oral NSAIDs Drug
Mfg OA RA JRA AS Pain PD Other Single Ingredient Agents celecoxib (Celebrex®) 1 Pfizer, generic X X X X X X diclofenac potassium 2 generic X X X X diclofenac potassium (Zipsor®) 3 Depo Med X diclofenac sodium (Voltaren®/XR®) 4, 5 generic X X X (IR) diclofenac submicronized (Zorvolex®) 6 Iroko X X diflunisal 7 generic X X X etodolac (Lodine®) 8 generic X X X X fenoprofen (Nalfon®) 9 generic X X X flurbiprofen 10 generic X X ibuprofen (Motrin®) 11 generic X X X X indomethacin (Indocin®) 12 generic X X X Treatment of painful shoulder (tendonitis, bursitis) and acute gout indomethacin (Tivorbex®) 13 Iroko X ketoprofen IR 14 generic X X  X X X ketoprofen ER 15 
FDA-Approved Indications: Oral NSAIDs (continued)
Drug Mfg OA RA JRA AS Pain PD Other Single Ingredient Agents (continued) ketorolac tromethamine 16 generic X Short-term (≤ 5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with ketorolac tromethamine injectable formulation (IM/IV) and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary meclofenamate 17 generic X X X X Treatment of idiopathic heavy menstrual blood loss mefenamic acid (Ponstel®) 18 Shionogi, generic X < 1 week X meloxicam (Mobic®) 19 generic X X X meloxicam submicronized (Vivlodex™) 20 Iroko X nabumetone 21 generic X X naproxen (Anaprox® / DS, Naprelan®, EC-/ Naprosyn®) 22, 23 generic X X X X X X Treatment of tendonitis, bursitis, and acute gout oxaprozin (Daypro®) 24 generic X X X piroxicam (Feldene®) 25 generic X X sulindac 26 generic X X X Treatment of acute painful shoulder and acute gouty arthritis tolmetin 27 generic X X X
Combination Agents
celecoxib/ menthol/ capsaicin * (CapXib Kit) 28 MAS X X X X X X celecoxib/ lidocaine/ menthol † (Lidoxib Kit) 29 MAS X X X X X X OA = Osteoarthritis, RA = Rheumatoid Arthritis, JRA = Juvenile Rheumatoid Arthritis (a.k.a Juvenile Idiopathic Arthritis [JIA]), AS = Ankylosing Spondylitis, PD = Primary Dysmenorrhea * Oral celecoxib co-packaged with topical menthol and capsaicin patch. The patch is indicated for temporary relief of minor aches and pains of the muscles and joints. † Oral celecoxib co-packaged with topical lidocaine 4%/menthol 1% patch. The patch is indicated for the temporary relief of pain associated with minor cuts, scrapes and skin irritations. diclofenac sodium DR/ capsaicin (Nudiclo™ TabPak) 30 Nucare X X X diclofenac sodium/ misoprostol (Arthrotec®) 31 Pfizer, generic X X Indicated for patients who are at high risk for NSAID-induced GI ulcers esomeprazole/ naproxen (Vimovo®) 32 Horizon X X X Indicated for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis and the reduction of risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers due to treatment with NSAIDs ibuprofen/ famotidine (Duexis®) 33 Horizon X X Indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers naproxen/ capsaicin/ menthol/ methyl salicylate ‡ (Sallus Pain Relief Collection) 34 Sallus X X X X X X Treatment of tendonitis, bursitis, and acute gout OA = Osteoarthritis, RA = Rheumatoid Arthritis, JRA = Juvenile Rheumatoid Arthritis (a.k.a Juvenile Idiopathic Arthritis [JIA]), AS = Ankylosing Spondylitis, PD = Primary Dysmenorrhea ‡ Oral naproxen co-packaged with topical Comfort Gel containing capsaicin, menthol, and methyl salicylate for topical pain relief.
diclofenac epolamine (Flector®) 36 Pfizer, generic X Topical treatment of acute pain due to minor strains, sprains, and contusions diclofenac sodium (Pennsaid® 1.5%, Pennsaid® 2% pump, Vopac 44, 45, 46 PureTek; International;
Nucare; Brand Management Products packaged as kits are discussed in the FDA Indications and Dosages sections, and components are addressed in the Pharmacology section. For other information regarding these products, please refer to the primary component throughout the text (e.g., celecoxib, diclofenac, naproxen).
GI adverse effects induced by NSAIDs lead to significant morbidity and mortality. Ulcers are found by endoscopy in 15 to 30% of patients who are using NSAIDs regularly, and the incidence of upper GI clinical events due to NSAIDs is 2.5 to 4.5%. In the United States, GI side effects due to NSAIDs in patients with arthritis account for approximately 107,000 hospitalizations and result in 16,500 deaths each year. 52 Products designed to lessen NSAID GI adverse reactions (Arthrotec, Vimovo, and Duexis) are available.
Celecoxib (Celebrex) , which selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, has equal efficacy to many of the other NSAIDs, but the issue of a better safety profile is unclear. Rofecoxib (September 2004) and valdecoxib (April 2005) have been removed from the market due to safety concerns. Celecoxib and all nonselective NSAIDs have come under greater scrutiny due to concerns over their cardiovascular safety.
Drug delivery technology overcomes the disadvantages of oral drug administration. First pass metabolism may impact oral administration and has the potential for systemic adverse effects. 53 A route of administration that bypasses the systemic exposure would provide an alternative that might improve patient adherence, minimize adverse effects, allow for a longer treatment interval, and serve as a substitute to conventional therapy.
NSAIDs reduce swelling and ease inflammation that can cause pain. NSAIDs are commonly used to treat osteoarthritis and pain from different etiologies. Oral and topical NSAIDs are among pharmacologic therapies recommended for OA by the 2012 American College of Rheumatology (ACR) OA of the hand, knee, and hip. 54 The 2013 treatment guidelines from the American Association of Orthopedic Surgeons for the treatment of osteoarthritis of the knee do not specify a specific NSAID or route of administration for osteoarthritis symptoms. 55 If the risk of GI adverse events is increased, the topical route is preferred among other treatment strategies.
PHARMACOLOGY
Both oral and topical NSAIDs inhibit the cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes that catalyze the synthesis of prostaglandins from arachidonic acid. These prostaglandins are partially responsible for the development of pain and inflammation associated with various medical conditions. COX-1 plays a role in maintaining normal gastric mucosa and influences kidney function. COX-2 activity is rapidly upregulated during inflammatory pain conditions and may be involved in the pathogenesis of some malignancies. 56, 57, 58, 59, 60 Selective COX-2 inhibitors provide anti-inflammatory effects and analgesia while theoretically resulting in fewer adverse effects than the nonselective NSAIDs. However, other prostaglandins may be affected that alter platelet aggregation, affecting the cardiovascular risk with some of the NSAIDs.
Zorvolex capsules contain diclofenac free acid, whereas other diclofenac products contain a salt of diclofenac (e.g., diclofenac potassium or sodium). The reduction in Zorvolex particle size increases surface area, leading to faster dissolution and absorption of the drug.
Vivlodex capsules contain submicronized meloxicam particles which allow a faster dissolution, resulting in an earlier time to maximum peak concentration compared to the tablet (approximately 2 hours versus 4 hours, respectively). 61 The inhibition of platelet aggregation seen with NSAIDs is due to the inhibition of COX-1 in platelets, causing decreased levels of platelet thromboxane A2 and increased bleeding time. The inhibition of platelet aggregation is reversible.
Esomeprazole, a component of Vimovo, works by inhibiting H+/K+-ATPase in gastric parietal cells, resulting in suppression of gastric acid secretions. This activity is dose-dependent. 62 Misoprostol, a component of Arthrotec, is a synthetic prostaglandin E1 analog. This agent counteracts the inhibition of prostaglandin synthesis noted with NSAIDs, increasing bicarbonate and mucus production. At doses of 200 mcg or greater, misoprostol is also noted to have significant anti-secretory properties, making the exact nature of its gastroprotective properties unclear. 63 Famotidine, a component of Duexis, is a competitive inhibitor of histamine-2 receptors, which thereby suppresses both the acid concentration and volume of gastric secretion. 64 Changes in pepsin secretion are proportional to volume output.
In peripheral sensory neurons, topical capsaicin depletes and limits reaccumulation of substance P, which is thought to be a primary mediator of pain impulses to the central nervous system (CNS). Thus, it limits local pain sensations as these sensations cannot be transmitted to the brain. Topical menthol also has a local effect, including mild analgesia, a cooling sensation, and an irritant/counter-irritant effect. Menthol also causes vasodilation. There are multiple mechanisms of menthol theorized on a cellular level; however, the exact mechanism of its effects is not well defined. 65 
Topical NSAIDs
Following a single application of diclofenac epolamine (Flector) to the upper inner arm, the peak plasma concentrations were noted within 10 to 20 hours. Diclofenac epolamine is 99% protein bound. Diclofenac sodium (Voltaren Gel, diclofenac gel component of co-packaged products) has 17 times less systemic exposure than the orally administered diclofenac. The amount of diclofenac sodium that is absorbed is on average 6% of that from oral diclofenac. Diclofenac sodium (Pennsaid) has about onethird of the systemic exposure compared to a topical diclofenac gel. The elimination half-life for topical diclofenac is approximately 12 hours. Diclofenac is metabolized through glucuronidation and eliminated through subsequent urinary and biliary excretion.
All NSAIDs may have a similar risk, which increases with longer duration of use. 163 Patients with cardiovascular disease or cardiovascular risk factors may be at greater risk. All NSAIDs are contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. NSAIDs cause an increased risk of potentially fatal bleeding, ulceration, and perforation of the stomach or intestines, occurring at any time during use and without warning. Elderly patients are at greater risk for serious GI events. In July 2015, the FDA issued a Safety Alert strengthening the existing warning on the increased risk of heart attack and stroke risk associated with NSAIDs. 164 In an August 2001 review of the COX-2 inhibitors and risk of cardiovascular events, the authors concluded that a prospective trial may be necessary to evaluate the potential risk of cardiovascular events with these agents. CLASS and VIGOR were designed to examine the GI effects of these medications, not the cardiovascular safety. 165, 166, 167 However, the VIGOR data were particularly concerning, since it showed a higher incidence of MI in rofecoxib (Vioxx®) patients compared to naproxen patients. The implications of these data were unclear because it was unknown if naproxen had a cardioprotective effect or if rofecoxib had adverse effects on the cardiovascular system. Data became available that brought the COX-2 inhibitors under more scrutiny; several retrospective studies and meta-analyses questioned the safety of these products. 168, 169, 170, 171 Newer studies evaluating these agents for use for other indications had more stringent monitoring in place for cardiovascular problems, which proved to be a critical step in evaluating their true effects. 172
Rofecoxib was withdrawn from the market after the discovery of higher cardiovascular risk with the agent in the APPROVe study. Not long after the withdrawal of rofecoxib, the cardiovascular effects of the other COX-2 inhibitors were called into question. Valdecoxib (Bextra®) was withdrawn from the market in February 2005 following extensive study of available clinical trials by the FDA. Celecoxib was allowed to remain on the market, but the advisement was given to use celecoxib at the lowest effective dose. 173, 174 The American Heart Association recommended soon afterward that any COX-2 inhibitors be reserved in patients with a history or risk of GI bleeding unless potential benefits of treatment are felt to outweigh the potential cardiovascular risks or nonselective NSAID therapy is insufficient. 175 The 2007 update to the American Heart Association Scientific Statement on the use of NSAIDs reiterates the reservation of COX-2 inhibitor use in patients with history of or at risk of CV disease and strengthens the point by suggesting COX-2 selective agents be used as a last resort with the prior steps being nonpharmacologic treatments (physical therapy, weight loss, exercise, etc.) followed by a stepped pharmacologic approach. 176 The first-line agents recommended are acetaminophen, aspirin, or a shortterm narcotic analgesic. If therapeutic alternatives are needed, physicians should consider the nonselective NSAIDs prior to the selective COX-2 inhibitor. This stepped approach focuses on the reported risk of cardiovascular events with the need for assessment of risk/benefit ratio at each step.
NSAIDs can lead to the onset of hypertension or worsening of existing hypertension. In addition, fluid retention and edema have been observed in some patients taking NSAIDS. Also, patients taking NSAIDs may have a decreased response to thiazide or loop diuretics. Therefore, monitoring patients with hypertension and patients at risk for the development of edema is recommended with all NSAIDs.
GI Toxicity
NSAIDs can cause an increased risk of serious GI adverse effects including bleeding, ulceration, and perforation of the stomach or intestine, which can be fatal. Serious GI toxicity can occur with or without warning with all NSAIDs. Patients at higher risk for the development of GI toxicity include patients on corticosteroids, anticoagulants, or long duration of NSAID therapy, as well as those with the following risk factors: smoking, alcoholism, poor health status, and older age. NSAIDs can exacerbate inflammatory bowel disease and should therefore be given with caution to patients with a history of this condition.
Renal Toxicity
Long-term use of NSAIDs can lead to renal papillary necrosis, renal insufficiency, acute renal failure, and other renal injuries. Patients with impaired renal function, heart failure, liver dysfunction, the elderly, and those taking diuretics, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers are at greatest risk for this reaction. The FDA notes that discontinuation of NSAID therapy usually is followed by recovery to the pretreatment state.
CNS adverse effects, including seizures, delirium, and coma, have been reported with famotidine in patients with moderate (creatinine clearance < 50 mL/min) and severe (creatinine clearance < 10 mL/min) renal impairment. Since the dosage of the famotidine component in Duexis is fixed, this product is not recommended in patients with moderate to severe renal insufficiency.
Naproxen/esomeprazole (Vimovo) is not recommended in patients with moderate or severe renal impairment.
Safety and efficacy of submicronized meloxicam (Vivlodex) has not been established in patients with severe renal impairment; use is not recommended. The maximum dose in patients on hemodialysis is 5 mg.
Hepatic Impairment
Elevations of 1 or more liver tests may occur in up to 15% of patients taking NSAIDs. Elevations of up to 3 times the upper limit of normal of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) have been reported in about 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis, and hepatic failure, some of them with fatal outcomes, have been reported.
Naproxen/esomeprazole (Vimovo) is not recommended in patients with severe hepatic impairment because esomeprazole doses should not exceed 20 mg daily in these patients.
Skin Reactions
NSAIDs can cause serious skin adverse events, such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrosis, which can be fatal. These conditions can occur without warning. NSAID therapy should be stopped at the first appearance of skin rash or other sign of hypersensitivity.
Hematological NSAID therapy should be stopped if active and clinically significant bleeding from any source occurs. Anemia is sometimes seen in patients taking NSAIDs. This may be due to fluid retention, occult or gross
Pre-existing Asthma
The use of aspirin in patients with aspirin-sensitive asthma has been associated with severe and possibly fatal bronchospasm. Since cross-reactivity between aspirin and the various NSAIDs has been reported in such aspirin-sensitive patients, oral and topical NSAIDs should not be administered to patients with this form of aspirin sensitivity and should be used with caution in patients with preexisting asthma.
Visual Disturbances
Blurred and/or diminished vision, scotomata, and/or changes in color vision have been reported with ibuprofen/famotidine (Duexis) . If a patient develops such complaints while on therapy, the drug should be discontinued, and the patient should have an ophthalmologic examination which includes central visual fields and color vision testing.
Nasal NSAIDs
Ketorolac tromethamine nasal spray (Sprix) is contraindicated in patients with a known hypersensitivity to ethylenediaminetetraacetic acid. Ketorolac nasal spray is contraindicated for use as a prophylactic analgesic before any major surgery. Probenecid decreases the clearance of ketorolac nasal spray; concomitant use is contraindicated. Similarly, the combination of pentoxifylline with ketorolac nasal spray is contraindicated due to increased bleeding risk.
Topical NSAIDs
Diclofenac formulations (Flector, Pennsaid, Voltaren Gel, diclofenac components of co-packaged products) carry a black box warning for cardiovascular (CV) and gastrointestinal risk. These agents may cause an increased risk of serious CV thrombotic events, myocardial infarction, and stroke, which can be fatal. Formulations are also contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery. These should not be applied to damaged skin or skin that is not intact.
Patients should be informed of the potential for adverse cardiovascular effects associated with all NSAIDs (e.g., risk of cardiovascular thrombotic events, new onset or worsening of hypertension, congestive heart failure, and edema). Diclofenac formulations should be used cautiously in patients with these conditions. NSAIDS, including diclofenac formulations, can cause serious GI adverse events, including inflammation, ulceration, and bleeding and perforation of the stomach, small intestine, or large intestine, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious GI events.
Diclofenac formulations should not be given to patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. They should also be avoided in patients with the aspirin triad (a nasal symptom complex typically occurring in asthmatic patients who fluconazole Concomitant use of fluconazole and celecoxib has been noted to increase the celecoxib plasma concentration as much as two-fold.
voriconazole
Concomitant use of voriconazole increases the systemic exposure to diclofenac. When concomitant voriconazole use is necessary, the total daily dose of diclofenac should not exceed the lowest recommended dose of diclofenac sodium/misoprostol (Arthrotec) 50 twice daily.
lithium
NSAIDs may produce an elevation of plasma lithium levels and a reduction in renal lithium clearance. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Patients should be monitored for signs of lithium toxicity when lithium and NSAIDs are given concurrently.
selective serotonin receptor inhibitors (SSRIs)
There is an increased risk of GI bleeding when SSRIs and NSAIDs are given concurrently.
warfarin
The effects of warfarin and NSAIDs on GI bleeding are synergistic, thereby increasing the risk of serious GI bleeding when used together.
methotrexate
Concomitant use of NSAIDs with methotrexate may increase the toxicity of methotrexate. Concomitant use of esomeprazole, a proton pump inhibitor, with methotrexate may increase and prolong serum levels of methotrexate and its metabolite, possibly leading to methotrexate toxicities. In high-dose methotrexate administration, a temporary withdrawal of the esomeprazole/naproxen (Vimovo) may be considered in some patients.
St John's Wort
Avoid concomitant use of esomeprazole/naproxen (Vimovo) with St John's Wort due to the potential reduction in esomeprazole levels.
rifampin Avoid concomitant use of esomeprazole/naproxen (Vimovo) with rifampin due to the potential reduction in esomeprazole levels.
tacrolimus
Concomitant administration of esomeprazole/naproxen and tacrolimus may increase the serum levels of tacrolimus.
gastric pH
Esomeprazole inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts, and digoxin).
lithium
methotrexate
Concomitant use of NSAIDs with methotrexate may increase the toxicity of methotrexate.
psychoactive drugs
Hallucinations have been reported in patients taking psychoactive drugs and ketorolac.
selective serotonin receptor inhibitors (SSRIs)
warfarin
Topical NSAIDs
All topical diclofenac formulations, including products co-packaged as a kit, have a similar profile to other NSAIDs and may interact with ACE inhibitors, aspirin, diuretics, lithium, methotrexate, and warfarin. Adverse effects data are obtained from prescribing information and therefore, should not be considered comparative or all inclusive. Incidences for the placebo group indicated in parentheses. nr = not reported *Adverse effects reported are based on the NSAID component.
Nasal NSAIDs
The most commonly reported adverse effects of ketorolac nasal spray (Sprix) (incidence > 2%) and occurring at a rate at least twice that of placebo are: nasal discomfort, rhinalgia, increased lacrimation, throat irritation, oliguria, rash, bradycardia, decreased urine output, increased ALT and/or AST, hypertension, and rhinitis. Ibuprofen (Motrin) has been tested in children 6months of age and older. It has not been shown to cause different adverse effects or problems than it does in adults. Over-the-counter strengths of ibuprofen are available for use in children.
Meloxicam (Mobic) is indicated in patients who weigh ≥ 60 kg. Safety and efficacy of indomethacin (Indocin) and mefenamic acid (Ponstel) in children 14 years of age and younger have not been established.
Safety and efficacy of diflunisal in children younger than 12 years of age have not been established.
Safety and efficacy of oxaprozin for the relief of signs and symptoms of JRA in patients 6 to 16 years of age are supported by extrapolating from adequate and well-controlled studies in adult rheumatoid arthritis patients. Safety and efficacy of oxaprozin in pediatric patients less than 6 years of age have not been established.
Safety and efficacy of tolmetin sodium have not been established in children less than 2 years of age.
Safety and efficacy of naproxen (EC-Naprosyn, Naprosyn, Anaprox, and Anaprox DS) in patients less than 2 years of age have not been established. The use of naproxen suspension (Naprosyn Suspension) is recommended for JRA in children 2 years or older because it allows for more flexible dose titration based on the child's weight. Single doses of 2.5 to 5 mg/kg, with total daily dose not exceeding 15 mg/kg/day, are well tolerated in pediatric patients over 2 years of age. Pharmacokinetic studies of naproxen were not performed in pediatric patients younger than 5 years of age. Per the pharmacokinetic section of the manufacturer prescribing information, naproxen delayed-release (EC-Naprosyn) has not been studied in patients under 18 years of age. Naproxen controlled-release (Naprelan) has not been studied in patients under 18 years of age.
Safety and efficacy have not been established in patients less than 18 years of age for the following agents: diclofenac (Zorvolex), diclofenac potassium (Zipsor), diclofenac sodium (Voltaren, Voltaren XR), diclofenac sodium/misoprostol (Arthrotec), fenoprofen (Nalfon), flurbiprofen, prescription strength ibuprofen (Motrin), ibuprofen/famotidine (Duexis), indomethacin (Tivorbex), ketoprofen, meclofenamate, meloxicam submicronized (Vivlodex), nabumetone, piroxicam (Feldene), and sulindac.
NSAIDs combined with proton pump inhibitors have no data supporting pediatric use; however, esomeprazole (Nexium®) is indicated for use in patients older than 1 year of age, and naproxen has been proven safe and effective in patients 2 years and older.
Pregnancy
All oral NSAIDs are in Pregnancy Category C prior to 30 weeks gestation, as is ibuprofen/famotidine and naproxen/esomeprazole. Diclofenac sodium/misoprostol (Arthrotec) is Category X and has a black box warning because misoprostol may cause abortions in pregnant women. All other NSAIDs are Category D in late pregnancy since they can cause premature closure of the ductus arteriosus and should therefore be avoided. Also, meclofenamate may be associated with miscarriage and minor skeletal malformations.
NSAIDs, including meloxicam (Mobic), may be associated with a reversible delay in ovulation. Therefore, in women who have difficulties conceiving, or who are undergoing investigation of infertility, use of meloxicam is not recommended.
Patients who are known or suspected to be poor CYP2C9 metabolizers based on previous history and/or experience with other CYP2C9 substrates (such as warfarin, phenytoin) should be administered celecoxib with caution. Consider starting treatment at half the lowest recommended dose in poor metabolizers. Consider using alternative management in JRA patients who are poor metabolizers.
Elderly
NSAIDs should be used with caution in elderly patients (65 years of age and older) since advancing age appears to increase the possibility of adverse effects. Elderly patients may be less tolerant of GI ulceration or bleeding than other individuals, and fatal GI reactions have been reported in this population. Indomethacin may cause confusion or, on rare occasions, psychosis.
NSAIDs and famotidine are known to be substantially excreted by the kidney, and the risk of toxic effects to NSAIDs may be greater in patients with renal function impairment. Because elderly patients are more likely to have decreased renal function, take care in dose selection, and it may be useful to monitor renal function.
For patients > 65 years, the dosage of ketorolac nasal spray (Sprix) is reduced to 15.75 mg (1 spray in only 1 nostril) every 6 to 8 hours for a daily maximum dose of 63 mg.
Nasal NSAIDs

Pediatrics
Safety and efficacy of ketorolac and ketorolac nasal spray (Sprix) in patients less than 17 years of age have not been established.
Pregnancy
Ketorolac nasal spray (Sprix) is Pregnancy Category C prior to 30 weeks gestation; thereafter, it is Category D in late pregnancy since it can cause premature closure of the ductus arteriosus and should therefore be avoided.
Renal Impairment
Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury.
Hepatic Impairment
Elevations of 1 or more liver tests may occur in up to 15% of patients taking NSAIDs including diclofenac formulations. Notable elevations of alanine aminotransferase (ALT) or aspartate aminotransferase (AST) (approximately 3 times the upper limit of normal) have been reported in about 1% of patients in clinical trials with NSAIDs. In addition, rare cases of severe hepatic reactions, 317,318,319,320,321,322,323,324,325,326,327,328,329,330,331,332,333,334,335,336,337,338,   339,340,341,342,343,344,345,346,347,348,349,350,351,352,353,354,355,356,357,358,359,360,361,362 OA, RA & AS: 750-1,000 mg once daily or 250-500 mg twice daily JRA: 5 mg/kg given twice daily; suspension is recommended for patients 2 years of age and older to allow for more accurate titration of the dose Pain, PD & acute tendonitis/bursitis: 1,000 mg to 1,500 mg once daily for a limited period; thereafter, the total daily dose should not exceed 1,000 mg Alternatively, a 500-550 mg first dose, followed by 500-550 mg every 12 hours or 250-275 mg every 6 to 8 hours Acute gout: The starting dose is 1,000-1,500 mg once daily, then 1,000 mg once daily Alternatively, 750-825 mg to start, followed by 250 
CLINICAL TRIALS
Studies were identified through searches performed on PubMed and review of information sent by manufacturers. Search strategy included the FDA-approved use of all drugs in this review. Randomized, comparative, controlled trials comparing agents within this class for the approved indications are considered the most relevant in this category. Studies included for analysis in the review were published in English, performed with human participants, and randomly allocated participants to comparison groups. In addition, studies must contain clearly stated, predetermined outcome measure(s) of known or probable clinical importance, use data analysis techniques consistent with the study question, and include follow-up (endpoint assessment) of at least 80% of participants entering the investigation. Despite some inherent bias found in all studies including those sponsored and/or funded by pharmaceutical manufacturers, the studies in this therapeutic class review were determined to have results or conclusions that do not suggest systematic error in their experimental study design. While the potential influence of manufacturer sponsorship and/or funding must be considered, the studies in this review have also been evaluated for validity and importance.
Oral NSAIDs
Comparative Efficacy of Non-selective NSAIDs
A number of studies have attempted to define relative efficacy of non-selective NSAIDs. 366, 367, 368, 369, 370 These efforts have consistently found that there is generally no significant difference in the efficacy among the non-selective NSAIDS. It was found that there was no statistically significant difference in efficacy, either between non-selective NSAIDs or between a non-selective NSAID and celecoxib. Additionally, no particular non-selective NSAID was associated with increased GI risk when compared to any other non-selective NSAID.
celecoxib (Celebrex) and diclofenac SR
In an Asian population, a 7-day, multicenter, double-blind, parallel-group trial randomized 370 patients with first-or second-degree ankle sprain occurring at or less than 48 hours prior to the first dose of study medication. 371 Patients received celecoxib 200 mg twice daily after a 400 mg loading dose or diclofenac SR 75 mg twice daily. Patients were required to demonstrate moderate to severe ankle pain on weight bearing by visual analogue scale (VAS) at baseline. The primary efficacy endpoint was the patient's assessment of ankle pain by VAS on day 4. Celecoxib was as effective as diclofenac SR in improving the signs and symptoms of ankle sprain; treatment differences were not statistically significant. The incidence of upper gastrointestinal adverse events was low in both treatment groups.
celecoxib (Celebrex) and diclofenac/omeprazole
Patients who used NSAIDs for arthritis and who presented with ulcer bleeding were screened for study inclusion in a randomized, double-blind trial. Once ulcers healed as determined by endoscopy, patients were randomized to receive either 200 mg of celecoxib twice daily plus daily placebo or 75 mg of diclofenac twice daily plus 20 mg of omeprazole daily for 6 months. 372 Patients were negative for Helicobacter pylori. Approximately 85% of each group had osteoarthritis. In the intention-to-treat analysis, which included 287 patients, the probability of recurrent bleeding during the 6month period was 4.9% for celecoxib patients and 6.4% for diclofenac/omeprazole patients (difference, -1.5 percentage points; 95% confidence interval (CI) for the difference, -6.8 to 3.8). The difference between the groups was not significant (p=0.60). A separate analysis of this group performed by the same investigators showed that the probability of recurrent ulcers in 6 months was 18.7% in the celecoxib group and 25.6% in the diclofenac/omeprazole group (p=0.21). 373
celecoxib (Celebrex), ibuprofen, and diclofenac
A total of 8,059 patients with OA and RA were enrolled in the double-blind, randomized, controlled study of Celecoxib Long-Term Arthritis Safety Study (CLASS). 374 A total of 4,573 patients received treatment for 6 months. Patients were randomly assigned to receive celecoxib 400 mg twice daily, ibuprofen 800 mg 3 times daily, or diclofenac 75 mg twice daily. Aspirin use (≤ 325 mg daily) for cardiovascular prophylaxis was permitted and was used by 20% of patients. Patients with active GI disease or renal, hepatic, or coagulation disorders were excluded. GI toxicity was defined as upper GI ulcers and ulcer complications including bleeding, perforation, and obstruction. For the entire patient population, the yearly incidence of upper GI complications was 0.76% and 1.45% for celecoxib and NSAIDs, respectively. The overall incidence of upper GI ulcer complications was not statistically different among the groups. When the upper GI complications data were combined with symptomatic gastroduodenal ulcers, celecoxib was found to have a lower annual incidence compared to the NSAIDs (2.08 versus 3.54%, respectively; p=0.02). For patients not taking aspirin, the yearly incidence of upper GI ulcer complications was significantly lower in the celecoxib group (0.44%) versus NSAIDs group (1.27%; p=0.04). Combining the multiple endpoints of the annualized incidence of upper GI ulcer complications and symptomatic ulcers for the patients not receiving aspirin, celecoxib group (1.4%, p=0.02) had significantly fewer events than the NSAIDs group (2.91%). In the patients taking aspirin, the annualized rate of upper GI ulcer complications for the 2 groups was similar (celecoxib, 2.01%; diclofenac, 2.12%; p=0.92). The yearly incidence of upper GI complications for patients taking aspirin was higher in both treatment groups than patients not taking aspirin. Chronic GI blood loss, GI intolerance, and renal or hepatic toxicity occurred less frequently in the celecoxib group. No difference in cardiovascular events was noted between celecoxib and NSAIDs, despite aspirin use.
celecoxib (Celebrex) and ketoprofen
In a 6 week, randomized, double-blind, placebo-controlled trial, celecoxib 100 mg twice daily and ketoprofen 100 mg twice daily were compared in 246 patients who had active ankylosing spondylitis without peripheral synovitis. 375 Decrease in pain and functional impairment was greater in the active treatment groups than in the placebo group, with a trend in favor of celecoxib when the 2 active treatments were compared. During treatment, epigastric pain was reported in 8, 14, and 13% of patients in the placebo, ketoprofen, and celecoxib groups, respectively.
celecoxib (Celebrex) and naproxen
The objective of the multicenter, randomized, double-blind, placebo-controlled study was to compare the efficacy and safety of celecoxib and naproxen for the treatment of OA of the hip. 376 In the trial, 1,061 patients were randomized to receive celecoxib 100, 200, or 400 mg/day, naproxen 1,000 mg/day, or placebo for 12 weeks. Patients were evaluated at baseline, 2 to 4 days after discontinuing previous NSAID or analgesic therapy, and after 2, 6, and 12 weeks of treatment. All doses of celecoxib and naproxen significantly improved the symptoms of OA at all time points compared with placebo. In terms of pain relief and improvement in functional capacity, celecoxib 200 mg/day and 400 mg/day were similarly efficacious and were as efficacious as naproxen. Both drugs were generally well tolerated.
In a similarly designed trial, 1,003 patients with OA of the knee received celecoxib 50, 100, or 200 mg twice daily, naproxen 500 mg twice daily, or placebo for 12 weeks. 377 All celecoxib doses were efficacious compared with placebo, although celecoxib 50 mg twice daily dosage regimen was minimally effective. Improvement observed with the higher dosing regimens of celecoxib was comparable to that seen with naproxen. All doses of celecoxib and naproxen were well tolerated.
In another double-blind, parallel-group, multicenter study, 537 patients with OA or RA were randomized to treatment with celecoxib 200 mg or naproxen 500 mg twice daily for 12 weeks. 378 The 2 agents produced similar improvements in Patient's and Physician's Global Assessments of arthritis efficacy. Incidence of adverse events and withdrawal rates did not differ significantly between treatments. Celecoxib produced a significantly lower incidence rate of both gastric (p<0.001) and duodenal (p<0.030) ulcers.
celecoxib (Celebrex), naproxen (Naprosyn), and diclofenac (Voltaren)
A total of 13,274 OA patients were randomly assigned to treatment with celecoxib 100 mg, celecoxib 200 mg, or nonselective NSAID therapy (diclofenac 50 mg or naproxen 500 mg) twice daily for 12 weeks. 379 In the double-blind trial, results from all primary efficacy assessments showed that both dosages of celecoxib were as effective as NSAIDs in treating OA. Significantly more ulcer complications (adjudication based on lesion) occurred within the nonselective NSAID group (0.8/100 patient-years) compared with the celecoxib group (0.1/100 patient-years; OR 7.02; 95% CI, 1.46 to 33.80, p=0.008).
The number of cardiovascular thromboembolic events was low and not statistically different between the groups.
celecoxib (Celebrex) and diclofenac (Zorvolex) in acute pain
A randomized, double-blind, placebo-controlled, parallel-arm, single center study in 428 patients with moderate-to-severe pain following bunionectomy evaluated patients randomized to diclofenac 18 mg or 35 mg 3 times daily, celecoxib 200 mg twice daily after a 400-mg loading dose, or placebo. 380 At 12 hours, pain intensity with diclofenac 18 and 35 mg was reduced from baseline by 48% and 51%, respectively, compared to 24% in the placebo group. At 24 hours, pain intensity was reduced by 69%, 73%, versus 52%, in diclofenac 18 and 35 mg versus placebo. All of these differences from placebo were statistically significant. Compared with celecoxib, overall reductions in pain intensity were greater with diclofenac 35 mg and similar with diclofenac 18 mg.
diclofenac (Zorvolex) and placebo in OA
A randomized, double-blind, parallel-group, placebo-controlled, 12-week, multicenter trial evaluated 305 patients with osteoarthritis of the hip or knee. 381 
celecoxib (Celebrex) and other NSAIDs in acute pain
Celecoxib has been studied in numerous head-to-head trials with other NSAIDs, such as ibuprofen, ketoprofen, and naproxen, in the treatment of various acute injuries, such as shoulder tendonitis/bursitis, ankle sprain, and tonsillectomy. 382, 383, 384, 385, 386 Efficacy between celecoxib and the NSAIDs was generally found to be comparable, with no clinical difference in the incidence of adverse effects.
Diclofenac sodium/misoprostol (Arthrotec) and diclofenac
Diclofenac was compared to the combination of diclofenac and misoprostol for efficacy, safety, and incidence of endoscopic upper GI ulcers in a 6 week, double-blind trial enrolling 572 patients with OA and a history of ulcers or erosions. 387 Patients were randomized to diclofenac 75 mg twice daily, diclofenac 50 mg/misoprostol 200 mcg 3 times daily, diclofenac 75 mg/misoprostol 200 mg twice daily, or placebo. All active treatment groups were more effective than placebo in relieving arthritis symptoms. Following the 6 week course of treatment, endoscopic ulcer rates (both gastric and duodenal ulcers) were as follows: diclofenac monotherapy (17%), diclofenac 50 mg with misoprostol (8%), diclofenac 75 mg with misoprostol (7%), and placebo (4%). A higher incidence of flatulence was observed in the diclofenac 75 mg with misoprostol group, whereas diclofenac 50 mg with misoprostol had a higher incidence of diarrhea.
A double-blind, randomized, parallel-group study was conducted to compare the safety and efficacy of a fixed combination of diclofenac 50 mg and misoprostol 200 mcg with a combination of diclofenac 50 mg and placebo in 361 patients with osteoarthritis. 388 Patients with no significant gastroduodenal lesions were enrolled and received study medication 2 or 3 times daily for 4 weeks. Post-treatment endoscopic examination of the gastroduodenal mucosa revealed ulcers in 4% of patients in the diclofenac/placebo group compared with none in the diclofenac/misoprostol group (p=0.015). There were no clinically or statistically significant differences between the 2 treatment groups in formal assessments of OA after either 2 or 4 weeks. Discontinuation of study drug due to adverse events was similar in each group (diclofenac/misoprostol group n=11, diclofenac/placebo group n=10). Eight patients in each group discontinued due to GI adverse events.
Similarly, another double-blind, randomized, parallel-group study compared the efficacy of diclofenac 50 mg/misoprostol 200 mcg or diclofenac 50 mg/placebo in treating the signs and symptoms of RA. 389 A total of 346 patients with RA who had been stabilized on diclofenac for at least 30 days were randomly assigned to receive either combination for 12 weeks. Diclofenac 50 mg/misoprostol 200 mcg demonstrated no statistically significant difference in efficacy in the treatment of the signs and symptoms of RA compared with diclofenac 50 mg/placebo.
Diclofenac sodium/misoprostol (Arthrotec) and nabumetone
In a 6 week trial, diclofenac sodium 75 mg with misoprostol 200 mcg twice daily was compared to nabumetone 1,500 mg once daily or placebo for ulcer rates in 1,203 patients with symptomatic OA of the hip or knee. 390 All patients enrolled had a history of endoscopically proven ulcers or erosions. Patients were evaluated by endoscopy at baseline, at withdrawal, or at the end of the 6 week time period. The incidence of duodenal and gastric ulcers confirmed with endoscopy was significantly lower in diclofenac/misoprostol group (4%) compared to nabumetone (11%). Duodenal ulcers were similar between the 2 active treatments. Gastric ulcers were significantly less with diclofenac/misoprostol (1%) compared to nabumetone (9%). Types of adverse events were similar for all treatment groups, with GI adverse events predominating. Diclofenac sodium 75 mg with misoprostol 200 mcg was well tolerated by the majority of patients. Withdrawals due to adverse effects were reported as 13% of patients in the diclofenac/misoprostol group, 10% in the nabumetone group, and 9% in the placebo group.
ibuprofen/famotidine (Duexis) and ibuprofen
Ibuprofen/famotidine was compared to ibuprofen in 2 multicenter, double-blind, active-controlled, randomized studies in patients who were expected to require daily administration of an NSAID for at least 6 months for conditions such as the following: OA, RA, chronic low back pain, chronic regional pain syndrome, and chronic soft tissue pain. 391 Duexis is FDA approved only for the treatment of OA and RA. The studies compared the incidence of upper GI (gastric and/or duodenal) ulcer formation in a total 1,533 patients, either as a primary or secondary endpoint. Patients were assigned in a 2:1 ratio to ibuprofen/famotidine (800 mg/26.6 mg) or ibuprofen (800 mg) 3 times a day for 24 consecutive weeks. Patient age ranged from 39 to 80 years (median age 55 years). Approximately 15% of the patients in both studies were taking concurrent low-dose aspirin (less than or equal to 325 mg daily) and 6% had a history of previous upper gastrointestinal ulcer. Helicobacter pylori status was negative at baseline; however, H. pylori status was not reassessed during the trials. In both trials ibuprofen/famotidine was associated with a statistically significant reduction in the risk of developing upper GI ulcers compared with ibuprofen alone. Each endpoint was analyzed in 2 fashions. In 1 analysis patients who terminated early, without an endoscopic evaluation within 14 days of their last dose of study drug, were classified as not having an ulcer. This analysis reported GI ulcer in 17.4 to 18.6% of patients in the ibuprofen/famotidine group, compared to 31 to 34.3% of patients in the ibuprofen group (p<0.0001). In the second analysis, those patients were classified as having an ulcer, which reported GI ulcer in 8.7 to 10.1% of patients in the ibuprofen/famotidine group, compared to 17.6 to 21.3% of patients in the ibuprofen group (p≤0.0004). The results of the patients that used low-dose aspirin were consistent with the overall findings of the study. In these clinical studies, 23% of patients 65 years of age and older who were treated with ibuprofen/famotidine developed an upper GI ulcer compared to 27% of those patients who received only ibuprofen. In addition, 25% of patients with a prior history of GI ulcer who were treated with ibuprofen/famotidine developed an upper GI ulcer compared to 24% of those patients who received ibuprofen only.
indomethacin (Tivorbex) and placebo
Efficacy of indomethacin (Tivorbex) was demonstrated for treatment of acute pain based on 2 phase 3 randomized, double-blind, placebo-controlled, parallel-arm, multicenter, studies that compared 20 mg of the drug 3 times daily, 40 mg 2 times daily, 40 mg 3 times daily, and placebo taken by patients with pain following bunionectomy. 392 There were a total of 835 patients, randomized equally across the treatment groups, enrolled in the 2 studies. The patients were a mean age of 40 years, ranging from 18 to 68 years, with at least a pain intensity rating of 40 mm on a 100 mm visual analog scale (VAS) during the 9 hour period after anesthetic block was discontinued following the surgery. Mean pain intensity in both studies ranged from 71 to 74 mm. One tablet of 10 mg/325 mg hydrocodone/acetaminophen was allowed every 4 to 6 hours as rescue medication. The use of rescue medication was greater in placebo-treated patients than in Tivorbex-treated patients. In both studies, all 3 Tivorbex dosages demonstrated efficacy in reduction of pain intensity compared to placebo, as measured by the sum of pain intensity difference over zero to 48 hours after the first dose.
meloxicam submicronized (Vivlodex) and placebo
A multicenter, randomized, double-blind, parallel-arm, placebo-controlled trial evaluated the safety and efficacy of meloxicam (Vivlodex) for the treatment of osteoarthritis pain of the hip or knee in adult patients (n=402). 393, 394 Adult patients were assigned meloxicam 5 mg, meloxicam 10 mg, or placebo orally once daily. The primary efficacy endpoint was the change in the Western Ontario and McMaster University Osteoarthritis Index (WOMAC) Pain Subscale score from baseline to 12 weeks. Both meloxicam doses (5 mg and 10 mg) significantly reduced pain compared to placebo at 12 weeks.
naproxen/esomeprazole (Vimovo) and naproxen enteric coated (EC)
The manufacturer performed 2 randomized, multicenter, double-blind studies comparing the incidence of gastric ulcer formation in patients with medical conditions expected to require daily NSAID therapy for at least 6 months. 395, 396 If patients (n=854) were less than 50 years old, they required documented history of gastric or duodenal ulcer within the past 5 years. Patients received naproxen/esomeprazole 500 mg/20 mg twice daily or enteric-coated naproxen 500 mg twice daily. About one quarter of the patients were taking low-dose aspirin also. Naproxen/esomeprazole patients showed statistically significant reductions in the 6 month cumulative incidence of gastric ulcers compared to naproxen EC (4.1-7.1% of patients with gastric ulcer versus 23.1-24.3%, respectively; p<0.001).
The manufacturer performed two, 12-week, randomized, double-blind, placebo-controlled studies to determine effectiveness of naproxen/esomeprazole in treating the signs and symptoms of OA of the knee. 397 Patients receiving naproxen/esomeprazole 500 mg/20 mg twice daily had significantly better results compared to placebo as measured by Western Ontario and McMaster Universities Arthritis Index (WOMAC) pain subscale and WOMAC physical function subscale, as well as a Patient Global Assessment score.
lansoprazole (Prevacid) and misoprostol (Cytotec)
A prospective, double-blind, multicenter, active-and placebo-controlled study evaluated 537 patients without H. pylori who were long-term users of NSAIDs and who had a history of gastric ulcer documented by endoscopy. 398 Patients were randomized to receive placebo, misoprostol 200 mcg 4 times a day, or lansoprazole 15 or 30 mg once daily for 12 weeks. Patients receiving lansoprazole (15 or 30 mg) remained free from gastric ulcer longer than those who received placebo (p<0.001), but for a shorter time than those who received misoprostol. By week 12, the percentages of gastric ulcer-free patients were as follows: placebo, 51%; misoprostol, 93%; lansoprazole 15 mg, 80%; and lansoprazole 30 mg, 82%. A significantly higher proportion of patients in the misoprostol group reported treatmentrelated adverse events and early withdrawal from the study. Therapy was successful for 69% of each active treatment group and 35% for the placebo group. Lansoprazole was superior to placebo for the prevention of NSAID-induced gastric ulcers but was not superior to misoprostol 800 mcg per day. When the poor compliance and potential adverse effects associated with misoprostol are considered, however, proton pump inhibitors (PPIs) and full-dose misoprostol are clinically equivalent. 399, 400 Nasal NSAIDs
ketorolac nasal spray (Sprix) and placebo
Ketorolac nasal spray was studied in a phase 3, randomized, multicenter, double-blind, placebocontrolled trial of 300 adults who had elective abdominal or orthopedic surgery. 401 Post-operatively, patients were treated with morphine dosed via patient controlled analgesia (PCA) on an as-needed basis. They were then randomized to the addition of ketorolac nasal spray or placebo, administered every 8 hours for 48 hours. Patients in the ketorolac nasal spray arm had a significantly reduced summed pain intensity difference over 48 hours compared to those in the placebo group. Patients in the ketorolac nasal spray arm required 36% less morphine over 48 hours than those treated with placebo.
A second phase 3, multicenter, double-blind, placebo-controlled study randomized 321 patients who had elective abdominal surgery to treatment with ketorolac nasal spray or placebo. 402 Post-operatively, patients were treated using morphine PCA on an as-needed basis. In addition, ketorolac nasal spray or placebo was administered every 6 hours for 48 hours. Patients in the ketorolac nasal spray group had a significantly greater reduction in summed pain intensity difference over 48 hours compared to those in the placebo group. Patients treated with ketorolac nasal spray required 26% less morphine over 48 hours compared to those in the placebo group.
Topical NSAIDs diclofenac patch (Flector)
A randomized, double-blind, multicenter, placebo-controlled trial was conducted in 120 patients with traumatic soft tissue injury within 3 hours post-injury. 403 Patients were randomized to twice daily treatment with either diclofenac patch or placebo over a period of 7 days. The primary efficacy endpoint was the area under the curve (AUC) for tenderness over the first 3 days. The diclofenac patch was significantly more effective than placebo (p<0.0001). The diclofenac patch produced rapid pain relief as reflected by the time to reach resolution of pain at the injured site, which was significantly shorter compared to placebo (p<0.0001). The most frequently observed adverse events with the use of diclofenac patch were mild, local cutaneous adverse events, occurring at the same frequency as placebo.
A multicenter, randomized, placebo-controlled, parallel-design study was conducted to assess the efficacy and safety of diclofenac patch applied directly to the injury site for the treatment of acute minor sports injury pain in 222 adult patients within 72 hours of the injury. 404 Either a diclofenac or placebo topical patch was applied directly to the skin overlying the injured site twice daily for 2 weeks. Measures of pain intensity were performed in a daily diary and at clinic visits on days 3, 7, and 14.
Diclofenac patch was superior to placebo patch in relieving pain. Statistical significance was seen on clinic days 3 (p=0.036) and 14 (p=0.048), as well as the daily diary pain ratings at days 3, 7, and 14 (p≤0.044). No statistically significant differences were seen in any safety or adverse effect measures with the diclofenac patch as compared to the placebo patch.
diclofenac solution (Pennsaid)
Patients (n=248) with osteoarthritis of the knee and at least moderate pain were randomly assigned to apply 1 solution to their painful knee for 4 weeks: diclofenac solution 1.5%, vehicle solution, or placebo solution. 405 The primary efficacy endpoint was pain relief, measured by the Western Ontario and McMaster Universities (WOMAC) LK3.0 Osteoarthritis Index pain subscale. In the intent-to-treat group, the mean change in pain score from baseline to final assessment was significantly greater for the patients who applied the diclofenac solution (-3.9; 95% confidence interval [CI], -4.8 to -2.9) than for those who applied the vehicle solution (-2.5; 95% CI, -3.3 to -1.7; p=0.023) or the placebo solution (-2.5; 95% CI, -3.3 to -1.7; p=0.016). The diclofenac solution also showed superiority to the vehicle and placebo solutions in physical function, stiffness, and in pain on walking. The Patient Global Assessment scores were significantly better for the patients who applied the diclofenac solution than for those who applied the other solutions (p=0.039 and 0.025, respectively). The diclofenac solution caused some skin irritation in 36% of patients. In a similarly designed 6-week study, diclofenac solution was again found to be superior to vehicle in 216 patients with osteoarthritis of the knee. 406 A 12-week trial in 216 patients with osteoarthritis of the knee came to the same conclusions. 407 A 12-week, double-blind, double-dummy, randomized controlled trial was performed in 775 subjects with symptomatic primary osteoarthritis of the knee. 408 This study compared diclofenac solution with a placebo solution, the vehicle solution, oral diclofenac, and the combination of oral diclofenac and diclofenac solution. Subjects applied study solutions 40 drops 4 times daily and took 1 study tablet daily for 12 weeks. Co-primary efficacy variables were WOMAC pain and physical function and a patient overall health assessment. Diclofenac solution was superior to placebo for pain (-6 versus -4.7; p=0.015), physical function (-15.8 versus -12.3; p=0.034), overall health (-0.95 versus -0.37; p<0.0001), and Patient Global Assessment (-1.36 versus -1.01; p=0.016), and was superior to vehicle for all efficacy variables. The most common adverse event associated with diclofenac solution was dry skin.
Fewer digestive system and laboratory abnormalities were observed with diclofenac solution than with oral diclofenac.
diclofenac gel (Voltaren Gel)
In a randomized, double-blind, placebo-controlled trial, 385 patients with primary osteoarthritis in the dominant hand were assigned to diclofenac 1% gel or vehicle to both hands 4 times daily for 8 weeks. 409 Primary outcome measures included osteoarthritis pain intensity (100 mm visual analog scale), total Australian/Canadian Osteoarthritis Hand Index (AUSCAN) score, and global rating of disease activity at 4 and 6 weeks. Diclofenac gel decreased pain intensity scores by 42 to 45%, total AUSCAN scores by 35 to 40%, and global rating of disease by 36 to 40%. Significant differences favoring diclofenac gel over vehicle were observed at week 4 for pain intensity and AUSCAN. At week 6, diclofenac gel significantly improved each primary outcome measure compared with vehicle. Secondary outcomes generally supported the primary outcomes. The most common adverse event was application site paresthesia.
In a randomized, double-blind, vehicle-controlled trial, 492 adults with symptomatic knee osteoarthritis were randomized to diclofenac gel 1% or vehicle 4 times daily for 12 weeks. 410 Primary efficacy outcomes at week 12 were the WOMAC pain subscale, WOMAC physical function subscale, and global rating of disease. At week 12, the diclofenac gel group had significant decreases versus the vehicle group in mean WOMAC pain (p=0.01), mean WOMAC physical function (p=0.001), and mean global rating of disease (p<0.001). Efficacy outcomes significantly favored diclofenac gel versus vehicle beginning at week 1. Application site reactions occurred in 5.1 and 2.5% of patients in the diclofenac gel and vehicle groups, respectively.
SUMMARY
The available clinical data do not suggest that any one NSAID offers a clear advantage compared to the others in terms of safety or efficacy, given the complex tradeoffs between the many benefits (e.g., pain relief, improved function, and improved tolerability) and harms (e.g., cardiovascular, renal, and gastrointestinal [GI]) involved. Adequate pain relief at the expense of an increase in cardiovascular risk could be an acceptable tradeoff for some patients. Others may consider even a marginal increase in cardiovascular risk unacceptable. When weighing the potential effects of any of these agents, the following patient factors should be considered prior to initiation of therapy: age, comorbid conditions, and concomitant medications. NSAIDs should be used in the lowest effective dose. Zorvolex, a lowdose diclofenac formulation, lacks comparison to other diclofenac formulations or other traditional NSAIDs.
The addition of misoprostol to diclofenac sodium (Arthrotec) in an attempt to reduce GI ulcers is efficacious, but many patients have difficulty tolerating the GI adverse effects, including diarrhea, associated with misoprostol. Esomeprazole/naproxen (Vimovo) has been approved to relieve the signs and symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), and ankylosing spondylitis (AS) and to decrease the risk of stomach (gastric) ulcers in patients at risk of developing stomach ulcers from treatment with NSAIDs. Data are available that support use of any proton pump inhibitor with concurrent NSAID administration. Ibuprofen/famotidine (Duexis) is the newest combination agent in this class and is indicated for the relief of signs and symptoms of OA and RA and to decrease the risk of developing upper GI ulcers.
Ketorolac nasal spray (Sprix) offers an alternative method of drug delivery.
The topical NSAIDs are indicated for treatment of acute pain conditions, including strains and sprains, as well as chronic pain conditions like osteoarthritis. For patients at risk for GI or cardiovascular events, topical administration of diclofenac (Flector, Pennsaid, Voltaren gel, and diclofenac-containing kits) provides an alternative method of drug delivery. 
